Abstract | BACKGROUND: METHODS: The enrolled subjects were 86 T2D patients [age; 59.8 ± 12.8 years, duration of diabetes; 15.8 ± 9.5 years, glycated hemoglobin (HbA1c); 8.5 ± 1.5%, body mass index (BMI); 27.3 ± 5.4 kg/m(2) (15.8 - 46.5 kg/m(2)), mean ± SD]. Among 86 subjects, liraglutide was introduced in 25 inpatients and 61 outpatients, and 46 subjects were followed for 2 years. Clinical parameters were measured at baseline and 3, 6, 9, 12, and 24 months after liraglutide introduction. The increase in liraglutide dosage and the additional usage of glucose-lowering agents depended on each attending physician. RESULTS: At 1 year after liraglutide introduction, 69 patients (80.2%) decreased body weight and 58 patients (67.4%) improved glycemic control. Body mass index (BMI) was changed 27.3 ± 5.4 kg/m(2) to 25.9 ± 4.8 kg/m(2) and percent reduction of body weight was significant and maintained over 4% at 2 years after liraglutide introduction. HbA1c was significantly decreased from 8.5 ± 1.5% to 7.7 ± 1.2% for 2 years. Liraglutide treatment tended to ameliorate lipid profile and hepatic enzymes. Stepwise regression analysis demonstrated that baseline BMI and previous insulin dose were positively associated with body weight reduction and baseline HbA1c was positively associated with reduction of HbA1c at 2 years after liraglutide introduction. CONCLUSIONS:
|
Authors | Kana Inoue, Norikazu Maeda, Yuya Fujishima, Shiro Fukuda, Hirofumi Nagao, Masaya Yamaoka, Ayumu Hirata, Hitoshi Nishizawa, Tohru Funahashi, Iichiro Shimomura |
Journal | Diabetology & metabolic syndrome
(Diabetol Metab Syndr)
Vol. 6
Issue 1
Pg. 95
( 2014)
ISSN: 1758-5996 [Print] England |
PMID | 25237400
(Publication Type: Journal Article)
|